LCTX Strangle Strategy
LCTX (Lineage Cell Therapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on AMEX.
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a novel hypoimmune induced pluripotent stem cell line for the development of a cell transplant candidate for the potential treatment of an undisclosed indication, as well as engages in the research and development of ILT1, an allogeneic cell transplant for the treatment of Type 1 Diabetes; and LCT-CON, an allogeneic cell transplant, as well as therapeutic products for retinal diseases, neurological diseases, ophthalmology, metabolic, and disorders and oncology. The company has a collaboration agreement with William Demant Invest for the preclinical development of ReSonance (ANP1). It also has a strategic collaboration with Factor Bioscience Inc. for the development of genetically engineered iPSC line for the company to utilize for differentiation into certain cell transplant product candidates.
LCTX (Lineage Cell Therapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $319.1M, a beta of 1.51 versus the broader market, a 52-week range of 0.85-2.09, average daily share volume of 1.5M, a public-listing history dating back to 1992, approximately 75 full-time employees. These structural characteristics shape how LCTX stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.51 indicates LCTX has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a strangle on LCTX?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current LCTX snapshot
As of June 26, 2026, spot at $1.27, ATM IV 226.70%, IV rank 44.88%, expected move 64.99%. The strangle on LCTX below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 21-day expiry.
Why this strangle structure on LCTX specifically: LCTX IV at 226.70% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 64.99% (roughly $0.83 on the underlying). The 21-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated LCTX expiries trade a higher absolute premium for lower per-day decay. Position sizing on LCTX should anchor to the underlying notional of $1.27 per share and to the trader's directional view on LCTX stock.
LCTX strangle setup
The LCTX strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With LCTX near $1.27, the first option leg uses a $1.33 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed LCTX chain at a 21-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 LCTX shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $1.33 | N/A |
| Buy 1 | Put | $1.21 | N/A |
LCTX strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
LCTX strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on LCTX. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on LCTX
Strangles on LCTX are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the LCTX chain.
LCTX thesis for this strangle
The market-implied 1-standard-deviation range for LCTX extends from approximately $0.44 on the downside to $2.10 on the upside. A LCTX long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current LCTX IV rank near 44.88% is mid-range against its 1-year distribution, so the IV signal is neutral; the strangle thesis on LCTX should anchor more to the directional view and the expected-move geometry. As a Healthcare name, LCTX options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to LCTX-specific events.
LCTX strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. LCTX positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move LCTX alongside the broader basket even when LCTX-specific fundamentals are unchanged. Always rebuild the position from current LCTX chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on LCTX?
- A strangle on LCTX is the strangle strategy applied to LCTX (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With LCTX stock trading near $1.27, the strikes shown on this page are snapped to the nearest listed LCTX chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are LCTX strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the LCTX strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 226.70%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a LCTX strangle?
- The breakeven for the LCTX strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current LCTX market-implied 1-standard-deviation expected move is approximately 64.99%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on LCTX?
- Strangles on LCTX are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the LCTX chain.
- How does current LCTX implied volatility affect this strangle?
- LCTX ATM IV is at 226.70% with IV rank near 44.88%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.